Cancer drug Jakafi may reverse hair loss

accreditation
Jakafi (ruxolitinib) is used to treat patients with polycythemia vera, a chronic type of bone marrow disease.
Jakafi (ruxolitinib) is used to treat patients with polycythemia vera, a chronic type of bone marrow disease.

Columbia University Medical Centre researchers found that the drug ruxolitinib (brand name: Jakafi) remedied hair loss in a small number of patients with alopecia areata, a disease in which immune cells destroy hair follicles.

Read: Hair extensions could lead to permanent hair loss

Alopecia areata can occur at any age and affects men and women. Patients typically lose patches of hair on the scalp, but may also lose facial and body hair. Currently, there are no known treatments to completely restore hair in these patients, who can suffer mental and emotional stress, the researchers said.

First, the researchers identified the immune cells that destroy hair follicles in people with alopecia areata. They also discovered that ruxolitinib – which is approved by the U.S. Food and Drug Administration to treat a bone marrow cancer called myelofibrosis – eliminated these immune cells.

Total hair regrowth

The study team first tested the drug in mice and then in a small number of people with moderate to severe alopecia areata (more than 30 percent hair loss). Within five months of starting treatment, three patients had total hair regrowth.

"We've only begun testing the drug in patients, but if the drug continues to be successful and safe, it will have a dramatic positive impact on the lives of people with this disease," study leader Dr. Raphael Clynes said.


Read: How your diet can improve the health of your hair

"We still need to do more testing to establish that ruxolitinib should be used in alopecia areata, but this is exciting news for patients and their physicians," he added.

"This disease has been completely understudied – until now, only two small clinical trials evaluating targeted therapies in alopecia areata have been performed, largely because of the lack of mechanistic insight into it."


Read more:

Fight frizz before it starts

Brazilian blowout a health threat

Hair removal for guys




We live in a world where facts and fiction get blurred
In times of uncertainty you need journalism you can trust. For only R75 per month, you have access to a world of in-depth analyses, investigative journalism, top opinions and a range of features. Journalism strengthens democracy. Invest in the future today.
Subscribe to News24
Voting Booth
Have you entered our Health of the Nation survey?
Please select an option Oops! Something went wrong, please try again later.
Results
Yes
30% - 9690 votes
No
70% - 23056 votes
Vote